MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
789.64%
Quick Ratio
789.64%
Cash Ratio
57.71%
Debt to Asset Ratio
42.88%
Unit: Thousand (K) dollars
Assets Breakdown
    • Short-term investments
    • In-process research and developm...
    • Cash and cash equivalents
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Warrant liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
6,803
6,152
22,808
3,669
Short-term investments
81,953
104,937
110,528
89,732
Prepaid expenses and other current assets
4,335
2,485
2,352
2,900
Total current assets
93,091
113,574
135,688
96,301
Operating lease asset, net
445
530
613
694
In-process research and development
32,386
32,386
32,386
32,386
Other assets
172
177
322
476
Total assets
126,094
146,667
169,009
129,857
Accounts payable
3,214
6,585
3,627
4,627
Current operating lease liabilities
381
369
358
346
Accrued expenses and other liabilities
8,194
6,504
14,359
9,323
Total current liabilities
11,789
13,458
18,344
14,296
Deferred tax liabilities
2,187
2,187
2,187
2,183
Non-current operating lease liabilities
86
186
283
376
Warrant liabilities
40,001
30,378
11,416
21,948
Total liabilities
54,063
46,209
32,230
38,803
Convertible preferred stock, value-Series XNon Voting Convertible Preferred Stock
2,151
2,151
2,151
2,151
Convertible preferred stock, value-Series X1Non Voting Convertible Preferred Stock
36,867
53,543
53,543
53,543
Common stock, 0.001 par value, 450,000,000 shares authorized at june 30, 2026 and 300,000,000 shares authorized at december 31, 2025 80,891,404 and 75,430,033 shares issued and outstanding at june 30, 2026 and december 31, 2025, respectively
81
76
75
60
Additional paid-in capital
504,904
484,988
482,189
426,047
Accumulated other comprehensive income (loss)
-114
-72
24
9
Accumulated deficit
-471,858
-440,228
-401,203
-390,756
Total stockholders equity
33,013
44,764
81,085
35,360
Total liabilities, convertible preferred stock and stockholders' equity
126,094
146,667
169,009
129,857
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$81,953K (-19.52%↓ Y/Y)Cash and cashequivalents$6,803K (18.50%↑ Y/Y)Prepaid expenses andother current assets$4,335K (13.07%↑ Y/Y)Total current assets$93,091K (-16.44%↓ Y/Y)In-process research anddevelopment$32,386K (0.00%↑ Y/Y)Operating lease asset, net$445K (-42.43%↓ Y/Y)Other assets$172K (-50.29%↓ Y/Y)Total assets$126,094K (-12.98%↓ Y/Y)Total liabilities,convertible preferred stock...$126,094K (-12.98%↓ Y/Y)Total liabilities$54,063K (39.05%↑ Y/Y)Convertible preferredstock, value-Series...$36,867K (-31.15%↓ Y/Y)Total stockholdersequity$33,013K (-34.41%↓ Y/Y)Convertible preferredstock, value-Series...$2,151K (0.00%↑ Y/Y)Accumulated deficit-$471,858K (-26.40%↓ Y/Y)Accumulated othercomprehensive income (loss)-$114K (-137.50%↓ Y/Y)Warrant liabilities$40,001K (77.69%↑ Y/Y)Total currentliabilities$11,789K (-14.07%↓ Y/Y)Deferred tax liabilities$2,187K (0.18%↑ Y/Y)Non-current operating leaseliabilities$86K (-81.58%↓ Y/Y)Additional paid-in capital$504,904K (19.19%↑ Y/Y)Common stock, 0.001 parvalue, 450,000,000...$81K (35.00%↑ Y/Y)Accrued expenses andother liabilities$8,194K (8.50%↑ Y/Y)Accounts payable$3,214K (-44.88%↓ Y/Y)Current operating leaseliabilities$381K (13.39%↑ Y/Y)

Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals, Inc. (ELDN)